References
Two AM, Wu W, Gallo RL, Hata TR. Rosacea: part I. Introduction, categorization, histology, pathogenesis, and risk factors. J Am Acad Dermatol. 2015;72(5):749–58. doi:10.1016/j.jaad.2014.08.028 (quiz 59–60).
van Zuuren EJ, Gupta AK, Gover MD, Graber M, Hollis S. Systematic review of rosacea treatments. J Am Acad Dermatol. 2007;56(1):107–15. doi:10.1016/j.jaad.2006.04.084.
Hayaishi O. Utilization of superoxide anion by indoleamine oxygenase-catalyzed tryptophan and indoleamine oxidation. Adv Exp Med Biol. 1996;398:285–9.
Wang Y, Liu H, McKenzie G, Witting PK, Stasch JP, Hahn M, et al. Kynurenine is an endothelium-derived relaxing factor produced during inflammation. Nat Med. 2010;16(3):279–85. doi:10.1038/nm.2092.
Heyes MP, Saito K, Major EO, Milstien S, Markey SP, Vickers JH. A mechanism of quinolinic acid formation by brain in inflammatory neurological disease: attenuation of synthesis from l-tryptophan by 6-chlorotryptophan and 4-chloro-3-hydroxyanthranilate. Brain. 1993;116(Pt 6):1425–50.
Muller AC, Maharaj H, Maharaj DS, Daya S. Aciclovir protects against quinolinic-acid-induced oxidative neurotoxicity. J Pharm Pharmacol. 2005;57(7):883–8. doi:10.1211/0022357056442.
Takci Z, Bilgili SG, Karadag AS, Kucukoglu ME, Selek S, Aslan M. Decreased serum paraoxonase and arylesterase activities in patients with rosacea. J Eur Acad Dermatol Venereol. 2015;29(2):367–70. doi:10.1111/jdv.12556.
Haas J, Meyding-Lamade U, Fath A, Stingele K, Storch-Hagenlocher B, Wildemann B. Acyclovir treatment of experimentally induced herpes simplex virus encephalitis: monitoring the changes in immunologic NO synthase expression and viral load within brain tissue of SJL mice. Neurosci Lett. 1999;264(1–3):129–32.
Steinhoff M, Buddenkotte J, Aubert J, Sulk M, Novak P, Schwab VD, et al. Clinical, cellular, and molecular aspects in the pathophysiology of rosacea. J Investig Dermatol Symp Proc. 2011;15(1):2–11. doi:10.1038/jidsymp.2011.7.
Sauermann G, Jaspers S, Hoppe U, Salzer B, Steinkraus V. Influence of NO-synthase antagonists in rosacea patients. J Invest Dermatol. 1997;4(108):657.
Smith JR, Lanier VB, Braziel RM, Falkenhagen KM, White C, Rosenbaum JT. Expression of vascular endothelial growth factor and its receptors in rosacea. Br J Ophthalmol. 2007;91(2):226–9. doi:10.1136/bjo.2006.101121.
Kuroki M, Voest EE, Amano S, Beerepoot LV, Takashima S, Tolentino M, et al. Reactive oxygen intermediates increase vascular endothelial growth factor expression in vitro and in vivo. J Clin Invest. 1996;98(7):1667–75. doi:10.1172/JCI118962.
Lu H, Han YJ, Xu JD, Xing WM, Chen J. Proteomic characterization of acyclovir-induced nephrotoxicity in a mouse model. PLoS One. 2014;9(7):e103185. doi:10.1371/journal.pone.0103185.
Guo YJ, Luo T, Wu F, Mei YW, Peng J, Liu H, et al. Involvement of TLR2 and TLR9 in the anti-inflammatory effects of chlorogenic acid in HSV-1-infected microglia. Life Sci. 2015;127:12–8. doi:10.1016/j.lfs.2015.01.036.
Kurt-Jones EA, Chan M, Zhou S, Wang J, Reed G, Bronson R, et al. Herpes simplex virus 1 interaction with Toll-like receptor 2 contributes to lethal encephalitis. Proc Natl Acad Sci USA. 2004;101(5):1315–20. doi:10.1073/pnas.0308057100.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Funding
Sayed Shahabuddin Hoseini was supported by the National Institutes of Health/National Cancer Institute Cancer Center Support Grant P30 CA008748.
Conflict of interest
Zohreh Sadat Badieyan and Sayed Shahabuddin Hoseini have no conflicts of interest directly relevant to the content of this article.
Rights and permissions
About this article
Cite this article
Badieyan, Z.S., Hoseini, S.S. Improvement of Rosacea During Acyclovir Treatment: A Case Report. Am J Clin Dermatol 18, 845–846 (2017). https://doi.org/10.1007/s40257-017-0315-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40257-017-0315-8